Literature DB >> 11432418

Quinolone resistance in Escherichia coli.

M Webber1, L J Piddock.   

Abstract

Escherichia coli is an important pathogen of animals and humans that causes great financial cost in food production by causing disease in food animals. The quinolones are a class of synthetic antimicrobial agents with excellent activity against Escherichia coli and other Gram-negative bacteria used in human and veterinary medicine. Different quinolones are used to treat various conditions in animals in different parts of the world. All members of this class of drug have the same mode of action: inhibition of topoisomerase enzymes, DNA Gyrase and Topoisomerase IV. Escherichia coli can become resistant to quinolones by altering the target enzymes, reducing permeability of the cell to inhibit their entry, or by actively pumping the drug out of the cell. All these resistance mechanisms can play a role in high-level fluoroquinolone resistance, however target site mutations appear to be most important. As all quinolones act in the same way resistance to one member of the class will also confer decreased susceptibility to all members of the family. Quinolone resistant Escherichia coli in animals have increased in numbers after quinolone introduction in a number of different case studies. The resistance mechanisms in these isolates are the same as those in resistant strains found in humans. Care needs to be taken to ensure that quinolones are used sparingly and appropriately as highly resistant strains of Escherichia coli can be selected and may pass into the food chain. As these drugs are of major therapeutic importance in human medicine, this is a public health concern. More information as to the numbers of quinolone resistant Escherichia coli and the relationship between resistance and quinolone use is needed to allow us to make better informed decisions about when and when not to use quinolones in the treatment of animals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432418     DOI: 10.1051/vetres:2001124

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  18 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.

Authors:  A M Haritova; N V Rusenova; P R Parvanov; L D Lashev; J Fink-Gremmels
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

3.  Molecular epidemiology of antimicrobial-resistant commensal Escherichia coli strains in a cohort of newborn calves.

Authors:  Deborah V Hoyle; Catherine M Yates; Margo E Chase-Topping; Esther J Turner; Sarah E Davies; J Chris Low; George J Gunn; Mark E J Woolhouse; Sebastian G B Amyes
Journal:  Appl Environ Microbiol       Date:  2005-11       Impact factor: 4.792

4.  Analysis of the gyrA gene of clinical Yersinia ruckeri isolates with reduced susceptibility to quinolones.

Authors:  Alicia Gibello; M Concepción Porrero; M Mar Blanco; Ana I Vela; Pilar Liébana; Miguel A Moreno; José F Fernández-Garayzábal; Lucas Domínguez
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

Review 5.  Multidrug resistant commensal Escherichia coli in animals and its impact for public health.

Authors:  Ama Szmolka; Béla Nagy
Journal:  Front Microbiol       Date:  2013-09-03       Impact factor: 5.640

6.  Complete Genome Sequences of Citrobacter braakii Strains GTA-CB01 and GTA-CB04, Isolated from Ground Beef.

Authors:  Prabh Basra; Adam Koziol; Alex Wong; Catherine D Carrillo
Journal:  Genome Announc       Date:  2015-01-08

7.  Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.

Authors:  Takae Shimizu; Kazuki Harada; Yasushi Kataoka
Journal:  Acta Vet Scand       Date:  2013-05-01       Impact factor: 1.695

8.  Correlation of minimum inhibitory concentrations between human and animal antimicrobials against Escherichia coli isolated from livestock.

Authors:  Manao Ozawa; Michiko Kawanishi; Mariko Uchiyama; Daisuke Mitsuya; Hitoshi Abo; Ryoji Koike; Mayumi Kijima
Journal:  J Vet Diagn Invest       Date:  2021-07       Impact factor: 1.569

9.  Antimicrobial resistance of Escherichia coli isolates from broiler chickens and humans.

Authors:  Tricia D Miles; Wayne McLaughlin; Paul D Brown
Journal:  BMC Vet Res       Date:  2006-02-06       Impact factor: 2.741

10.  Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.

Authors:  KaNa Sang; HaiHong Hao; LingLi Huang; Xu Wang; ZongHui Yuan
Journal:  Front Vet Sci       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.